| | Business Summary | | Quantech
Ltd.
is
completing
development
of
a
system
that
is
expected
to
run
tests
for
a
number
of
different
medical
conditions.
The
Company
calls
its
system
the
FasTraQ.
The
FasTraQ
consists
of
an
instrument
that
sits
on
the
top
of
a
counter
or
cart
and
reads
PrePaQ
disposable
test
cartridges
developed
by
Quantech.
Each
Quantech
PrePaQ
test
cartridge
will
contain
from
one
to
four
different
medical
tests
such
as
those
for
a
heart
attack
or
pregnancy.
Hand-held
communication
devices
called
ReaLinQ
communicators
provide
real
time
test
results
directly
from
the
FasTraQ
instrument
to
the
medical
staff
members
treating
a
patient. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Quantech,
Ltd.
is
a
development
stage
company
which
commercializes
its
surface
plasmon
resonance
technology
for
the
medical
diagnostic
market.
For
the
nine
months
ended
3/01,
revenues
totaled
$68
thousand,
vs.
none.
Net
loss
applicable
to
Common
increased
61%
to
$11.3
million.
Revenues
benefitted
from
the
sale
of
an
evaluation
system
and
licensing
income.
Higher
loss
reflects
increased
research
and
development
costs
due
to
the
initial
development
work
at
HTS
BioSystems. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| James Lyons, 70
Chairman | -- | Robert Case, 56
CEO | $144K | Edward Zeman
CFO | -- | Thomas Witty, Ph.D., 53
Exec.
VP R&D | 144K | Rita Hofberg
VP of Sales and Marketing | -- | | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/q/qqqq.ob.gif)